A phase I clinical trial with nivolumab showed an objective response rate (ORR) of 15% in patients with MF, but 0% in patients with other forms of CTCL, indicating the significant role that PD-1 plays in MF [104]. The gene discussed is PDCD1; the disease is mycosis fungoides.